Molluscum contagiosum - Strategies for Treatment (Video 3:38 minutes)

Article

Molluscum contagiosum: they’re embarrassing and contagious-- and treatable. Details for a successful outcome here.

Molluscum contagiosum: they’re embarrassing and contagious-and treatable.
Details for a successful outcome here.

For more webinar videos, click here.

Recent Videos
Paul Kruszka, MD
Herbert Bravo, MD
Tina Tan, MD
Paul Kruszka, MD, MPH, FACMG
Stephanie Anne Deutsch, MD, MS, MSCR, FAAP
H. Westley Phillips, MD
David Turkewitz, MD
H. Westley Phillips, MD
David Turkewitz, MD
Related Content
Image credit: Production Perig

COVID-19 Therapy Roundtable: Defining the Virus Today and Treatment Options

Joshua Fitch, Senior Editor ;John Parkinson
December 5th 2024
Article

In our latest roundtable series, we cover different therapies around COVID-19 treatment and prevention.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
FDA grants Rare Pediatric Disease to 101-PGC-005 for systemic juvenile idiopathic arthritis | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

FDA grants Rare Pediatric Disease to 101-PGC-005 for systemic juvenile idiopathic arthritis

Joshua Fitch, Senior Editor
December 4th 2024
Article

101-PGC-005 is Type IA prodrug of dexamethasone that targets CD206+ macrophages.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
J&J submits applications for guselkumab to treat plaque psoriasis, jPsA in childrenLatest revision | Image Credit: © pimentos - © pimentos - stock.adobe.com.

J&J submits applications for guselkumab to treat plaque psoriasis, jPsA in children

Joshua Fitch, Senior Editor
December 3rd 2024
Article

The submission to treat PsO is for children aged 6 years and up while the jPsA submission is to treat children aged 5 years and older.

Saol Therapeutics submits NDA for SL1009 to treat Pyruvate Dehydrogenase Complex Deficiency | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

Saol Therapeutics submits NDA for SL1009 to treat Pyruvate Dehydrogenase Complex Deficiency

Joshua Fitch, Senior Editor
December 3rd 2024
Article

If approved, SL1009 has the potential to be the first approved medication for PDCD, and would be available as an oral solution.

© 2024 MJH Life Sciences

All rights reserved.